Attorney's Docket No.: 15665-009US1 / PD53655US02

Applicant: Lars Pettersson Serial No.: To be assigned Filed: July 31, 2006 Page: 3 of 24

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) An anti-estrogenic compound of the general formula I

I

wherein

A is a 8-22 atoms long substituent, which wherein substituent A is defined by comprises D_{1-6} , wherein D is chosen from the group comprising consisting of R4-C(O)R4, R4S(O)₀₋₂R4, N(R4)₃, R4OR4 and R4(C6H4)R4 R4(C6H4)R4;

wherein R4 independently represents a bond, ef H, or a halogenated or non-halogenated, saturated or unsaturated, mono-, di-, or trivalent C1-C12 hydrocarbon;

B',B" are H,H, or H,O-R3, or O-R3,H, or H,F, or together represent =O;

R1 is H, or a potentially metabolically unstable group chosen from the group comprising consisting of a straight, branched, or cyclic C1-C6 alkyl, C1-C6 acyl, benzoyl, sulphamoyl, or and N-acetyl-sulphamoyl;

Filed : July 31, 2006
Page : 4 of 24

R2 is H, or a potentially metabolically unstable group chosen from the group comprising C1-C6 acyl or benzoyl;

R3 is H, or C1-C3 alkyl, or a potentially metabolically unstable group chosen from the group comprising C1-C6 acyl, benzoyl, sulphamoyl, or N-acetyl-sulphamoyl; and

X is methylene or a single bond, or

pharmaceutically acceptable salts of the compounds of the general formula I.

2. (Currently amended) A compound according to claim 1, wherein A is

$$-(CH_2)_{4-6}N((CH_2)_{0-2}H)(CH_2)_{2-4}S(O)_{0-2}(CH_2)_{2-4}(CF_2)_{1-3}CF_3CF_3.$$

3. (Currently amended) A compound according to any of claims 1-2 claim 1, wherein A is

$$-(CH_2)_{7-11}S(O)_{0-2}(CH_2)_{2-4}(CF_2)_{1-3}CF_3\underline{CF_3}\underline{CF_3}.$$

4. (Currently amended) A compound according to any of claims 1-2 claim 1, wherein A is

$$-(CH_2)_{8-12}C(O)N((CH_2)_{0-2}H)(CY_2)_{2-6}Y$$

wherein Y is chosen from H or F.

- 5. (Currently amended) A compound according to any of claims 1-4, wherein R1 is hydrogen, or methyl, or acetyl, or benzoyl, or sulphamoyl, or N-acetyl-sulphamoyl.
- 6. (Currently amended) A compound according to any of claims 1-5 any of claims 1-4, wherein R3 is H, of methyl, or a potentially metabolically unstable group chosen from the group comprising C1-C6 acyl, benzoyl, sulphamoyl, or N-acetyl-sulphamoyl.

Filed : July 31, 2006

Page : 5 of 24

7. (Currently amended) A compound according to claim 1,

wherein A is

 $-(CH_2)_{4-6}N((CH_2)_{0-2}H)(CH_2)_{2-4}S(O)_{0-2}(CH_2)_{2-4}(CF_2)_{1-3}CF_3-CF_3$

OF

 $-(CH_2)_{7-11}S(O)_{0-2}(CH_2)_{2-4}(CF_2)_{1-3}-CF_3-CF_3$

or

 $-(CH_2)_{8-12}C(O)N((CH_2)_{0-2}H)(CY_2)_{2-6}Y(CY_2)_{2-6}Y$

wherein Y is chosen from H or F or F,

or

 $-(CH_2)_{8-9}CH(CO_2H)(CH_2)_{2-5}(CF_2)_{1-3}CF_3-CF_3$

or

 $-C_6H_4-p-O(CH_2)_{3-6}S(O)_{0-2}(CH_2)_{2-4}(CF_2)_{1-3}-CF_2-CF_3$

or

 $-C_6H_4$ -p-O(CH₂)₂NMe₂;

R1 is hydrogen, or methyl, or acetyl, or benzoyl, or sulphamoyl, or N-acetyl-sulphamoyl;

R2 is hydrogen; and

R3 is H, or a potentially metabolically unstable group chosen from the group comprising consisting of C1-C6 acyl, benzoyl, sulphamoyl, or and N-acetyl-sulphamoyl.

8. (Currently amended) A compound according to claim 1,

wherein A is

 $-(CH_2)_{4-6}N(CH_3)(CH_2)_{2-4}S(O)_{0-2}(CH_2)_{2-4}(CF_2)_{1-3}-CF_3-CF_3$

or

 $-(CH_2)_{7-11}S(O)_{0-2}(CH_2)_{2-4}(CF_2)_{1-3}-CF_3-CF_3$

or

 $-(CH_2)_{10}C(O)N(CH_3)(CY_2)_{2-6}Y(CY_2)_{2-6}Y$

wherein Y is chosen from H or F,

or

Applicant: Lars Pettersson Attorney's Docket No.: 15665-Serial No.: To be assigned 009US1 / PD53655US02

Filed : July 31, 2006

Page : 6 of 24

 $-(CH_2)_{8-9}CH(CO_2H)(CH_2)_{2-5}(CF_2)_{1-3}CF_3;$ B',B" are H,H; of H,O-R3; of O-R3,H; or H,F; R1 is H, or methyl, or sulphamoyl; and R3 is H, or methyl, or acyl;

9. (Currently amended) A compound according to elaims claim 1, wherein A is

$$-(CH_2)_{4-6}N(CH_3)(CH_2)_3S(O)_{0-2}(CH_2)_3CF_2CF_3CF_3.$$

or

$$-(CH_2)_{8-10}S(O)_{0-2}(CH_2)_{2-4}(CF_2)_{1-3}-CF_3CF_3$$

or

$$-(CH_2)_{8-9}CH(CO_2H)(CH_2)_{2-5}(CF_2)_{1-3}-CF_3$$

and

R3 is H.

(Currently amended) A compound according to any one of claims 1 9 claim 1 chosen 10. from the group comprising consisting of:

11-(3,16α-Dihydroxy-17-methylene-estra-1,3,5(10)-triene-7α-yl)-undecanoic acid n-butylmethyl-amide,

11-(3,16α-Dihydroxy-17-methylene-estra-1,3,5(10)-triene-7α-yl)-undecanoic acid n-butylmethyl-amide 3-O-benzoate,

11-(3,16 α -Dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 α -yl)-undecanoic acid (2,2,3,3,4,4,4heptafluoro)-n-butyl-methyl-amide,

 $3,16\alpha$ -Dihydroxy-17-methylene- 7α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)thio]nonyl]-estra-1,3,5(10)-triene,

Serial No.: To be assigned Filed: July 31, 2006 Page: 7 of 24

 $3,16\alpha$ -Dihydroxy-17-methylene- 7α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene,

 $3,16\alpha$ -Dihydroxy-17-methylene- 7α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene 3-O-acetate,

 $3,16\alpha$ -Dihydroxy-17-methylene- 7α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene 3-O-sulfamate,

 $3,16\alpha$ -Dihydroxy-17-methylene- 7α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene 3-O-benzoate,

 $3,16\alpha$ -Dihydroxy-17-methylene- 7α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfonyl]nonyl]-estra-1,3,5(10)-triene,

 $3,16\alpha$ -Dihydroxy-17-methylene- 7α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]octyl]-estra-1,3,5(10)-triene,

 7α -[9-[(2,2,3,3,4,4,4-Heptafluoro-n-butyl)sulfinyl]nonyl]-3,16 α -dihydroxy-17-methylene-estra-1,3,5(10)-triene,

 $3,16\alpha$ -Dihydroxy-17-methylene- 7α -[9-[(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)sulfonyl]nonyl]-estra-1,3,5(10)-triene,

 $3,16\alpha$ -Dihydroxy-17-methylene- 7α -[9-[(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)sulfonyl]nonyl]-estra-1,3,5(10)-triene,

Serial No.: To be assigned Filed: July 31, 2006
Page: 8 of 24

 $3,16\alpha$ -Dihydroxy-17-methylene- 7α -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

- $3,16\alpha$ -Dihydroxy-17-methylene- 7α -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,
- $3,16\alpha$ -Dihydroxy-17-methylene- 7α -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene 3-O-sulfamate,
- $3,16\alpha$ -Dihydroxy-17-methylene- 7α -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene 3-O-benzoate,
- $3,16\alpha$ -Dihydroxy-17-methylene- 7α -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfonyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,
- $3,16\alpha$ -Dihydroxy-17-methylene- 7α -[5-[N-methyl-N-3-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,
- $3,16\alpha$ -Dihydroxy-17-methylene- 7α -[5-[N-methyl-N-3-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,
- 11-(3,16 α -Dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 α -yl)-2-(4,4,5,5,5-pentafluoro-n-pentyl)-undecanoic acid,
- 11-(3,16 α -Dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 α -yl)-2-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-undecanoic acid,

Applicant: Lars Pettersson Attorney's Docket No.: 15665-009US1 / PD53655US02

Serial No.: To be assigned Filed : July 31, 2006

Page : 9 of 24

11-(3,16 α -Dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 α -yl)-2-(3,3,4,4,5,5,6,6,6nonafluoro-n-hexyl)-undecanoic acid,

nonafluoro-n-hexyl)-decanoic acid,

11-(3,16 α -Dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 α -yl)-2-(3,3,4,4,5,5,6,6,6nonafluoro-n-hexyl)-undecanoic acid methylester,

 $2-[9-(3,16\alpha-Dihydroxy-17-methylene-estra-1,3,5(10)-triene-7\alpha-yl)-nonyl]-2-(3,3,4,4,5,5,6,6,6-1)$ nonafluoro-n-hexyl)-malonic acid,

11-(3,6α,16α-Trihydroxy-17-methylene-estra-1,3,5(10)-triene-7α-yl)-undecanoic acid n-butylmethyl-amide,

 $3,6\alpha,16\alpha$ -Trihydroxy-17-methylene- 7α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)thio]nonyl]-estra-1,3,5(10)-triene,

 $3,6\alpha,16\alpha$ -Trihydroxy-17-methylene- 7α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene,

 $3,6\alpha,16\alpha$ -Trihydroxy-17-methylene- 7α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene 3-O-sulfamate,

 $3,6\alpha,16\alpha$ -Trihydroxy-17-methylene- 7α -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)propylamino]-pentyl]-estra-1,3,5(10)-triene,

Filed : July 31, 2006
Page : 10 of 24

 $3,6\alpha,16\alpha$ -Trihydroxy-17-methylene- 7α -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene 3-O-sulfamate,

3,6α,16α-Trihydroxy-17-methylene-7α-[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

 $3,6\alpha,16\alpha$ -Trihydroxy-17-methylene- 7α -[5-[N-methyl-N-3-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

11- $(3,6\alpha,16\alpha$ -Trihydroxy-17-methylene-estra-1,3,5(10)-triene- 7α -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-undecanoic acid,

10- $(3,6\alpha,16\alpha$ -Trihydroxy-17-methylene-estra-1,3,5(10)-triene- 7α -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-decanoic acid,

11- $(6\beta$ -Fluoro-3, 16α -dihydroxy-17-methylene-estra-1,3,5(10)-triene- 7α -yl)-undecanoic acid n-butyl-methyl-amide,

 6β -Fluoro-3,16α-dihydroxy-17-methylene-7α-[9-[(4,4,5,5,5-pentafluoro-n-pentyl)thio]nonyl]-estra-1,3,5(10)-triene,

 6β -Fluoro-3,16α-dihydroxy-17-methylene-7α-[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene,

 6β -Fluoro-3, 16α -dihydroxy-17-methylene-7α-[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

Applicant: Lars Pettersson Attorney's Docket No.: 15665-Serial No.: To be assigned 009US1 / PD53655US02

Filed : July 31, 2006 : 11 of 24

Page

 6β -Fluoro-3,16α-dihydroxy-17-methylene-7α-[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-methyl-N-3-(4,4,5,5,5-pentafluoro-n-methyl-N-3-(4,4,5,5,5-pentafluoro-n-methyl-N-3-(4,4,5,5,5-pentafluoro-n-methyl-N-3-(4,4,5,5,5-pentafluoro-n-methyl-N-3-(4,4,5,5,5-pentafluoro-n-methyl-N-3-(4,4,5,5,5-pentafluoro-n-methyl-N-3-(4,4,5,5,5-pentafluoro-n-methyl-N-3-(4,4,5,5,5-pentafluoro-n-methyl-N-3-(4,4,5,5,5-pentafluoro-n-methyl-N-3-(4,4,5,5,5-pentafluoro-n-methyl-N-3-(4,4,5,5,5-pentafluoro-n-methyl-N-3-(4,4,5,5,5-pentafluoro-n-methyl-N-3-(4,4,5,5,5-pentafluoro-n-methyl-N-3-(4,4,5,5,5-pentafluoro-n-methyl-N-3-(4,4,5,5,5-pentafluoro-n-methyl-N-3-(4,4,5,5,5-pentafluoro-n-methyl-N-3-(4,4,5,5-pentafluoro-n-methyl-N-3-(4,4,5,5-pentafluoro-n-methyl-N-3-(4,4,5,5-pentafluoro-n-methyl-N-3-(4,4,5,5-pentafluoro-n-methyl-N-3-(4,4,5,5-pentafluoro-n-methyl-N-3-(4,4,5-pentafluor pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

 6β -Fluoro-3,16α-dihydroxy-17-methylene-7α-[5-[N-methyl-N-3-(3,3,4,4,5,5,6,6,6-nonafluoron-hexyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene.

11-(6 β -Fluoro-3,16 α -dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 α -yl)-2-(3,3,4,4,5,5,6,6,6nonafluoro-n-hexyl)-undecanoic acid,

10- $(6\beta$ -Fluoro-3,16 α -dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 α -yl)-2-(3,3,4,4,5,5,6,6,6)nonafluoro-n-hexyl)-decanoic acid,

 $3,6\beta,16\alpha$ -Trihydroxy-17-methylene- 7α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene,

 $3,6\beta,16\alpha$ -Trihydroxy-17-methylene- 7α -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)propylamino]-pentyl]-estra-1,3,5(10)-triene,

 $3,6\beta,16\alpha$ -Trihydroxy-17-methylene- 7α -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-npentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

11- $(3,6\beta,16\alpha$ -Trihydroxy-17-methylene-estra-1,3,5(10)-triene- 7α -yl)-2-(3,3,4,4,5,5,6,6,6)nonafluoro-n-hexyl)-undecanoic acid,

11-(17-(1,2-Ethylene)-3,16α-dihydroxy-estra-1,3,5(10)-triene-7α-yl)-undecanoic acid n-butylmethyl-amide,

Serial No.: To be assigned Filed: July 31, 2006 Page: 12 of 24

11-(17-(1,2-Ethylene)-3,16 α -dihydroxy-estra-1,3,5(10)-triene-7 α -yl)-undecanoic acid n-butyl-methyl-amide 3-O-benzoate,

11-(17-(1,2-Ethylene)-3,16 α -dihydroxy-estra-1,3,5(10)-triene-7 α -yl)-undecanoic acid (2,2,3,3,4,4,4-heptafluoro)-n-butyl-methyl-amide,

17-(1,2-Ethylene)-3,16 α -dihydroxy-7 α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)thio]nonyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-3,16 α -dihydroxy-7 α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-3,16 α -dihydroxy-7 α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene 3-O-acetate,

 $17-(1,2-Ethylene)-3,16\alpha-dihydroxy-7\alpha-[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene 3-O-sulfamate,$

17-(1,2-Ethylene)-3,16 α -dihydroxy-7 α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfonyl]nonyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-3,16 α -dihydroxy-7 α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]octyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-7 α -[9-[(2,2,3,3,4,4,4-heptafluoro-n-butyl)sulfinyl]nonyl]-3,16 α -dihydroxy-estra-1,3,5(10)-triene,

Filed : July 31, 2006 Page : 13 of 24

17-(1,2-Ethylene)-3,16 α -dihydroxy-7 α -[9[(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)sulfonyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-3,16 α -dihydroxy-7 α -[9-[(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)sulfonyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-3,16 α -dihydroxy-7 α -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-3,16 α -dihydroxy-7 α -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene 3-O-benzoate,

17-(1,2-Ethylene)-3,16 α -dihydroxy-7 α -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene 3-O-acetate,

17-(1,2-Ethylene)-3,16 α -dihydroxy-7 α -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene 3-O-sulfamate,

17-(1,2-Ethylene)-3,16 α -dihydroxy-7 α -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-3,16 α -dihydroxy-7 α -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfonyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-3,16 α -dihydroxy-7 α -[5-[N-methyl-N-3-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

Filed : July 31, 2006
Page : 14 of 24

17-(1,2-Ethylene)-3,16 α -dihydroxy-7 α -[5-[N-methyl-N-3-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

11-(17-(1,2-Ethylene)-3,16 α -dihydroxy-estra-1,3,5(10)-triene-7 α -yl)-2-(4,4,5,5,5-pentafluoro-n-pentyl)-undecanoic acid,

11-(17-(1,2-Ethylene)-3,16 α -dihydroxy-estra-1,3,5(10)-triene-7 α -yl)-2-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-undecanoic acid,

11-(17-(1,2-Ethylene)-3,16 α -dihydroxy-estra-1,3,5(10)-triene-7 α -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-undecanoic acid,

10-(17-(1,2-Ethylene)-3,16 α -dihydroxy-estra-1,3,5(10)-triene-7 α -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-decanoic acid,

11-(17-(1,2-Ethylene)-3,16 α -dihydroxy-estra-1,3,5(10)-triene-7 α -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-undecanoic acid methylester,

2-[9-(17-(1,2-Ethylene)-3,16 α -dihydroxy-estra-1,3,5(10)-triene-7 α -yl)-nonyl]-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-malonic acid,

11-(17-(1,2-Ethylene)-3,6 α ,16 α -trihydroxy-estra-1,3,5(10)-triene-7 α -yl)-undecanoic acid n-butyl-methyl-amide,

11-(17-(1,2-Ethylene)-3,6 α ,16 α -trihydroxy-estra-1,3,5(10)-triene-7 α -yl)-undecanoic acid (2,2,3,3,4,4,4-heptafluoro)-n-butyl-methyl-amide,

Filed : July 31, 2006
Page : 15 of 24

17-(1,2-Ethylene)-3,6 α ,16 α -trihydroxy-7 α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)thio]nonyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-3,6 α ,16 α -trihydroxy-7 α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-3,6 α ,16 α -trihydroxy-7 α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene 3-O-sulfamate,

17-(1,2-Ethylene)-3,6 α ,16 α -trihydroxy-7 α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfonyl]nonyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-7 α -[9-[(2,2,3,3,4,4,4-heptafluoro-n-butyl)sulfinyl]nonyl]-3,6 α ,16 α -trihydroxy-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-3,6 α ,16 α -trihydroxy-7 α -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-3,6α,16α-trihydroxy-7α-[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene 3-O-sulfamate,

17-(1,2-Ethylene)-3,6α,16α-trihydroxy-7α-[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-3,6 α ,16 α -trihydroxy-7 α -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfonyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

Filed : July 31, 2006 Page : 16 of 24

11-(17-(1,2-Ethylene)-3,6 α ,16 α -trihydroxy-estra-1,3,5(10)-triene-7 α -yl)-2-(4,4,5,5,5-pentafluoro-n-pentyl)-undecanoic acid,

11-(17-(1,2-Ethylene)-3,6 α ,16 α -trihydroxy-estra-1,3,5(10)-triene-7 α -yl)-2-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-undecanoic acid,

10-(17-(1,2-Ethylene)-3,6 α ,16 α -trihydroxy-estra-1,3,5(10)-triene-7 α -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-decanoic acid,

11-(17-(1,2-Ethylene)-3,6 α ,16 α -trihydroxy-estra-1,3,5(10)-triene-7 α -yl)-2-(4,4,5,5,5-pentafluoro-n-pentyl)-undecanoic acid methylester,

11-(17-(1,2-Ethylene)-3,6 α ,16 α -trihydroxy-estra-1,3,5(10)-triene-7 α -yl)-2-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-undecanoic acid methylester,

2-[9-(17-(1,2-Ethylene)-3,6 α ,16 α -trihydroxy-estra-1,3,5(10)-triene-7 α -yl)-nonyl]-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-malonic acid,

11-(17-(1,2-Ethylene)-6 β -fluoro-3,16 α -dihydroxy-estra-1,3,5(10)-triene-7 α -yl)-undecanoic acid n-butyl-methyl-amide,

11-(17-(1,2-Ethylene)-6 β -fluoro-3,16 α -dihydroxy-estra-1,3,5(10)-triene-7 α -yl)-undecanoic acid (2,2,3,3,4,4,4-heptafluoro)-n-butyl-methyl-amide,

17-(1,2-Ethylene)-6 β -fluoro-3,16 α -dihydroxy-7 α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)thio]nonyl]-estra-1,3,5(10)-triene,

Filed : July 31, 2006 Page : 17 of 24

17-(1,2-Ethylene)-6 β -fluoro-3,16 α -dihydroxy-7 α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-6 β -fluoro-3,16 α -dihydroxy-7 α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene 3-O-sulfamte,

17-(1,2-Ethylene)-6 β -fluoro-3,16 α -dihydroxy-7 α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfonyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-6 β -fluoro-3,16 α -dihydroxy-7 α -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-6 β -fluoro-3,16 α -dihydroxy-7 α -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene 3-O-sulfamate,

17-(1,2-Ethylene)-6 β -fluoro-3,16 α -dihydroxy-7 α -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-6 β -fluoro-3,16 α -dihydroxy-7 α -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfonyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

11-(17-(1,2-Ethylene)-6 β -fluoro-3,16 α -dihydroxy-estra-1,3,5(10)-triene-7 α -yl)-2-(4,4,5,5,5-pentafluoro-n-pentyl)-undecanoic acid,

11-(17-(1,2-Ethylene)-6 β -fluoro-3,16 α -dihydroxy-estra-1,3,5(10)-triene-7 α -yl)-2-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-undecanoic acid,

Serial No.: To be assigned Filed: July 31, 2006 Page: 18 of 24

11-(17-(1,2-Ethylene)-6 β -fluoro-3,16 α -dihydroxy-estra-1,3,5(10)-triene-7 α -yl)-2-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-undecanoic acid methylester,

17-(1,2-Ethylene)-3,6 β ,16 α -trihydroxy-7 α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)thio]nonyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-3,6 β ,16 α -trihydroxy-7 α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-3,6β,16α-trihydroxy-7α-[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-3,6 β ,16 α -trihydroxy-7 α -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

11-(17-(1,2-Ethylene)-3,6 β ,16 α -trihydroxy-estra-1,3,5(10)-triene-7 α -yl)-2-(4,4,5,5,5-pentafluoro-n-pentyl)-undecanoic acid,

11-(17-(1,2-Ethylene)-3,6 β ,16 α -trihydroxy-estra-1,3,5(10)-triene-7 α -yl)-2-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-undecanoic acid,

17-(1,2-Ethylene)-3,16 α -dihydroxy-6-keto-7 α -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-3,16 α -dihydroxy-6-keto-7 α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene,

Attorney's Docket No.: 15665-009US1 / PD53655US02

Applicant: Lars Pettersson Serial No.: To be assigned Filed: July 31, 2006 Page: 19 of 24

17-(1,2-Ethylene)-3,16 α -dihydroxy-6-keto-7 α -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-3,16 α -dihydroxy-6 α -methoxy-7 α -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-3,16 α -dihydroxy-6 α -methoxy-7 α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene,

17-(1,2-Ethylene)-3,16 α -dihydroxy-6 β -methoxy-7 α -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene, and

17-(1,2-Ethylene)-3,16 α -dihydroxy-6 β -methoxy-7 α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene.

11. (Currently amended) An intermediate compound of the general formula VIII:

wherein R1, R2 and X are as defined in claim 1

Serial No.: To be assigned Filed: July 31, 2006 Page: 20 of 24

R1 is H, or a potentially metabolically unstable group chosen from the group consisting of a straight, branched, or cyclic C1-C6 alkyl, C1-C6 acyl, benzoyl, sulphamoyl, and N-acetyl-sulphamoyl;

R2 is H, or a potentially metabolically unstable group chosen from the group comprising C1-C6 acyl or benzoyl; and

X is methylene or a single bond.

- 12. (Currently amended) A compound according to any one of claims 1 10 claim 1 for use as a medicament.
- 13. (Currently amended) Use of a compound according to any one of claims 1 10 claim 1 for the manufacturing of a medicament for the treatment of an estrogen related disorder or condition that benefits from antiestrogen treatment.
- 14. (Currently amended) Use according to claim 13, wherein the estrogen related disorder or condition is chosen from the group eomprising consisting of estrogen dependent breast cancer, anovulatory infertility, menstrual disorders, male pattern baldness, dysfunctional uterine bleeding, endometrial polyps, benign breast disease, uterine leiomyomas, adenomyosis, ovarian cancer, endometrial cancer, melanoma, prostate cancer, cancers of the colon, CNS cancers, endometriosis, polycystic ovary syndrome, infertility and contraception in males.
- 15. (Original) Use according to claim 13 or 14, wherein the estrogen related disorder is estrogen dependent breast cancer.
- 16. (Currently amended) A pharmaceutical composition comprising a compound according to any one of claims 1–10 claim 1, admixed with one or more pharmaceutically acceptable excipients or carriers.

Applicant: Lars Pettersson Attorney's Docket No.: 15665-Serial No.: To be assigned 009US1 / PD53655US02

Filed : July 31, 2006 Page : 21 of 24

17. (Original) A pharmaceutical composition according to claim 16, wherein the excipients are chosen from the group comprising filling agents, lubricants, flavours, colourings, sweetenings, buffers, acidifying agents, diluents and preservatives.

- 18. (Currently amended) A pharmaceutical composition according to any one of claims 16-17, for administration orally, intramuscularly, intravenously, intraperitoneally or subcutaneously, via implants, rectally, intranasally, transdermally, or vaginally; preferably orally, transdermally or intranasally. vaginally.
- 19. (Currently amended) A method of treatment comprising administration of a pharmaceutically effective amount of compound according to elaim 1 10 claim 1 or a pharmaceutical composition according to elaim 16 17 claim 16 to a subject suffering from an estrogen dependent disorder or condition.
- 20. (Original) A method of treatment according to claim 19, wherein the estrogen dependent disorder or condition is chosen from the group comprising estrogen dependent breast cancer, anovulatory infertility, menstrual disorders, male pattern baldness, dysfunctional uterine bleeding, endometrial polyps, benign breast disease, uterine leiomyomas, adenomyosis, ovarian cancer, endometrial cancer, melanoma, prostate cancer, cancers of the colon, CNS cancers, endometriosis, polycystic ovary syndrome, infertility and contraception in males.
- 21. (Currently amended) A method of treatment according to elaim 19 or 20 claim 19, wherein the estrogen dependent disorder is estrogen dependent breast cancer.